Abstract
Antitumor treatments, including chemotherapy, targeted therapy, immunotherapy, surgery, and radiotherapy, are essential in cancer care but frequently carry the risk of liver injury. Such complications can severely impact patient prognosis and quality of life. To address this, the Oncology Hepatology Committee of the China Anti-Cancer Association (CACA) has developed comprehensive technical guidelines for the holistic management of liver protection. These guidelines synthesize the latest research and clinical experience to provide standardized protocols for the diagnosis, prevention, and treatment of treatment-related liver injury.
Introduction: The Challenge of Hepatotoxicity in Oncology
Liver injury is a frequent and severe complication of modern cancer therapy. Whether caused by the direct chemical toxicity of chemotherapy, the immune-mediated inflammation of checkpoint inhibitors, or the physical trauma of surgery and radiation, hepatotoxicity often forces the suspension or discontinuation of life-saving treatments.
The challenge is twofold: first, the clinical impact of treatment interruption directly worsens patient prognosis; second, the mechanisms of injury vary wildly across different modalities. Historically, management has been fragmented. The CACA guidelines bridge this gap, advocating for a "holistic integrative" approach that treats liver protection as an integral component of the overall oncological strategy.
Standardized Severity Grading
A cornerstone of effective management is the objective assessment of injury severity. The guidelines adopt the Common Terminology Criteria for Adverse Events (CTCAE) 5.0 framework to establish clear thresholds for biochemical markers like serum bilirubin and AST/ALT levels.
These grades (G1 to G5) serve as the basis for clinical decision-making, determining when a treatment can safely continue and when it must be paused or permanently halted. For example, clear biochemical markers like ALT > 8x ULN are established as thresholds for stopping potentially hepatotoxic drugs.
Management of Immune-Mediated Hepatitis (IMH)
With the rise of Immune Checkpoint Inhibitors (ICIs), clinicians face a unique form of liver injury: immune-mediated hepatitis. Unlike traditional drug toxicity, IMH results from enhanced immune activity rather than direct chemical damage. The CACA guidelines provide specific, tiered recommendations for monitoring and intervention based on the severity grade.
As shown in the recommendations, while G1 injury allows for continued therapy with increased monitoring (1–2 times per week), G4 injury necessitates the permanent discontinuation of immunotherapy and daily monitoring.
Key Clinical Insights
Hepatitis Reactivation
A critical safety measure highlighted in the guidelines is mandatory screening for Hepatitis B (HBV) and Hepatitis C (HCV) before initiating targeted or immunotherapy. These treatments can reactivate latent viruses, potentially leading to acute, life-threatening liver failure.
Surgical and Radiation Safety
For local treatments, the guidelines define "safe volume" parameters for hepatectomy using Standardized Liver Volume (SLV). In radiotherapy, they establish dosage limits—such as keeping the average liver dose below 28-32 Gy for primary hepatocellular carcinoma—to prevent Radiation-Induced Liver Disease (RILD).
Pharmacological Toolkit
The guidelines recommend a tailored pharmacological approach using specific agents based on the injury type, including antioxidants (Bicyclol), anti-inflammatories (Glycyrrhizic acid), and membrane stabilizers (Polyene phosphatidylcholine).
Conclusion and Future Directions
The CACA technical guidelines provide a vital roadmap for clinicians to navigate the complexities of liver protection in cancer care. However, the authors note that further research is needed to refine these protocols. Areas for future work include validating the RUCAM scale specifically for chemotherapy-induced injury, refining the "time window" for advanced interventions like artificial liver support, and elucidating the molecular pathways of targeted therapy-induced hepatotoxicity.
Summary updated